Bladder Cancer Journal Vol. 10, Issue 1
Ensuring Successful Biomarker Studies in Bladder Preservation Clinical Trials for Non-muscle...
Read MoreSelect Page
by Bladder Cancer Journal | Mar 2024
Ensuring Successful Biomarker Studies in Bladder Preservation Clinical Trials for Non-muscle...
Read Moreby Bladder Cancer Journal | Dec 2023
What is a Bladder Cancer Molecular Subtype? Abstract:Â BACKGROUND: Several molecular...
Read Moreby Bladder Cancer Journal | Sep 2023
Immune Checkpoint Inhibitors in Metastatic Bladder and Other Solid Malignancies: How Long is...
Read Moreby Bladder Cancer Journal | Jun 2023
Novel Delivery Mechanisms for Existing Systemic Agents and Emerging Therapies in Bladder Cancer...
Read Moreby Colin P. N. Dinney, MD | May 2023
Colin P.N. Dinney, MD, discusses the promise of neoadjuvant chemotherapy for muscle-invasive bladder cancer in the genomic era.
Read Moreby Seth P. Lerner, MD, FACS | Apr 2023
Seth P. Lerner, MD, discusses the optimal therapy for T1 high-grade (T1HG) bladder cancer and considers the future of treatment.
Read Moreby Bladder Cancer Journal | Mar 2023
Recent Advances in the Classification of Bladder Cancer – Updates from the 5th Edition of the...
Read Moreby Peter Black, MD, FACS, FRCSC | Mar 2023
Peter Black, MD, FACS, FRCSC, discusses trimodal therapy (TMT) as a bladder-sparing option for some patients with muscle-invasive bladder cancer (MIBC).
Read Moreby Seth P. Lerner, MD, FACS | Mar 2023
Seth P. Lerner, MD, provides a comprehensive history of Bacille Calmette-Guerin (BCG) and SWOG ’s innovation in bladder cancer over the past three decades.
Read Moreby Seth P. Lerner, MD, FACS | Feb 2023
In this 20-minute video, Seth P. Lerner, MD, Professor of Urology and Vice-chair for Faculty Affairs in the Scott Department of Urology, and Director of Urologic Oncology and the Multidisciplinary Bladder Cancer Program at Baylor University, discusses risk-adapted transurethral resection of bladder tumor (TURBT). He assesses TURBT’s role in staging and treatment and considers its use in bladder preservation.
Read Moreby Raj S. Pruthi, MD, MHA, FACS | Feb 2023
Dr. Raj S. Pruthi discusses the obstacles to achieving optimal outcomes for patients undergoing radical cystectomy. He meticulously analyzes the multifaceted challenges encountered in the preoperative, intraoperative, and postoperative phases of radical cystectomy, a complex surgical procedure primarily performed for muscle-invasive bladder cancer.
Preoperative factors that can impede optimal outcomes, including patient comorbidities, nutritional status, and the importance of thorough preoperative assessment and optimization. He emphasizes the role of prehabilitation in enhancing patient readiness for surgery.
During the intraoperative phase, Dr. Pruthi highlights the technical intricacies of radical cystectomy, stressing the importance of surgical expertise and meticulous technique in minimizing perioperative complications. He discusses the role of minimally invasive techniques, such as robotic-assisted surgery, in potentially reducing blood loss, shortening hospital stays, and enhancing recovery.
Postoperatively, Dr. Pruthi identifies key factors that influence recovery and long-term outcomes. He underscores the significance of effective pain management, early mobilization, and comprehensive postoperative care in mitigating complications. Dr. Pruthi also discusses the challenges related to urinary diversion, including the management of neobladder and ileal conduit complications, and the impact of these diversions on patients’ quality of life.
Read Moreby Bladder Cancer Journal | Dec 2022
Predicting Recurrence and Progression in Patients with Non-Muscle-Invasive Bladder Cancer:...
Read More